Literature DB >> 18505970

Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?

Brian D Lawenda1, Kara M Kelly, Elena J Ladas, Stephen M Sagar, Andrew Vickers, Jeffrey B Blumberg.   

Abstract

Despite nearly two decades of research investigating the use of dietary antioxidant supplementation during conventional chemotherapy and radiation therapy, controversy remains about the efficacy and safety of this complementary treatment. Several randomized clinical trials have demonstrated that the concurrent administration of antioxidants with chemotherapy or radiation therapy reduces treatment-related side effects. Some data indicate that antioxidants may protect tumor cells as well as healthy cells from oxidative damage generated by radiation therapy and some chemotherapeutic agents. However, other data suggest that antioxidants can protect normal tissues from chemotherapy- or radiation-induced damage without decreasing tumor control. We review some of the data regarding the putative benefits and potential risks of antioxidant supplementation concurrent with cytotoxic therapy. On the basis of our review of the published randomized clinical trials, we conclude that the use of supplemental antioxidants during chemotherapy and radiation therapy should be discouraged because of the possibility of tumor protection and reduced survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18505970     DOI: 10.1093/jnci/djn148

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  126 in total

1.  Beta-carotene antioxidant use during radiation therapy and prostate cancer outcome in the Physicians' Health Study.

Authors:  Danielle N Margalit; Julie L Kasperzyk; Neil E Martin; Howard D Sesso; John Michael Gaziano; Jing Ma; Meir J Stampfer; Lorelei A Mucci
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-11       Impact factor: 7.038

Review 2.  Phytochemicals in the oncology setting.

Authors:  Catherine E Ulbricht; Wendy Chao
Journal:  Curr Treat Options Oncol       Date:  2010-12

3.  Antioxidant supplement use after breast cancer diagnosis and mortality in the Life After Cancer Epidemiology (LACE) cohort.

Authors:  Heather Greenlee; Marilyn L Kwan; Lawrence H Kushi; Jun Song; Adrienne Castillo; Erin Weltzien; Charles P Quesenberry; Bette J Caan
Journal:  Cancer       Date:  2011-09-27       Impact factor: 6.860

4.  A conserved antioxidant response element (ARE) in the promoter of human carbonyl reductase 3 (CBR3) mediates induction by the master redox switch Nrf2.

Authors:  Qiuying Cheng; James L Kalabus; Jianping Zhang; Javier G Blanco
Journal:  Biochem Pharmacol       Date:  2011-10-05       Impact factor: 5.858

5.  The Impact of Nutrition on the Development and Prognosis of Breast Cancer.

Authors:  Hans Hauner; Dagmar Hauner
Journal:  Breast Care (Basel)       Date:  2010-12-08       Impact factor: 2.860

Review 6.  Integrative medicine: complementary therapies and supplements.

Authors:  Barrie R Cassileth; Jyothirmai Gubili; K Simon Yeung
Journal:  Nat Rev Urol       Date:  2009-04       Impact factor: 14.432

7.  Effect of naturopathic and nutritional supplement treatment on tumor response, control, and recurrence in patients with prostate cancer treated with radiation therapy.

Authors:  Donald P Braun; Digant Gupta; Timothy C Birdsall; Michele Sumner; Edgar D Staren
Journal:  J Altern Complement Med       Date:  2012-10-04       Impact factor: 2.579

8.  Sound preconditioning therapy inhibits ototoxic hearing loss in mice.

Authors:  Soumen Roy; Matthew M Ryals; Astrid Botty Van den Bruele; Tracy S Fitzgerald; Lisa L Cunningham
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

9.  Sulforaphane and related mustard oils in focus of cancer prevention and therapy.

Authors:  Ingrid Herr; Vladimir Lozanovski; Philipp Houben; Peter Schemmer; Markus W Büchler
Journal:  Wien Med Wochenschr       Date:  2012-12-07

10.  Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer.

Authors:  Kuzhuvelil B Harikumar; Ajaikumar B Kunnumakkara; Gautam Sethi; Parmeswaran Diagaradjane; Preetha Anand; Manoj K Pandey; Juri Gelovani; Sunil Krishnan; Sushovan Guha; Bharat B Aggarwal
Journal:  Int J Cancer       Date:  2010-07-15       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.